Abstract
Hyperbilirubinemia is a frequent occurrence following allogeneic stem cell transplantation (alloSCT), often attributed to primary liver damage. This study investigates early bilirubinemia (EB) as a potential marker of systemic endothelial dysfunction. Analyzing a training cohort of 873 patients and a validation cohort of 388 patients, researchers identified a critical total bilirubin threshold of 3.6 mg/dL within the first 28 days post-transplant. EB above this level significantly predicted non-relapse mortality (NRM) and overall survival (OS), independent of traditional endothelial complications like veno-occlusive disease. Furthermore, EB correlated strongly with endothelial biomarkers (Angiopoietin-2, ST2) and the Endothelial Activation and Stress Index (EASIX). These findings suggest that EB is not merely a sign of liver stress but a manifestation of a systemic endothelial pathomechanism.
Introduction
Allogeneic stem cell transplantation (alloSCT) remains a curative but high-risk therapy for hematologic malignancies. Non-relapse mortality (NRM), driven by graft-versus-host disease (GVHD) and infectious complications, is a major barrier to success. Recent research has increasingly pointed toward the vascular endothelium—the cellular lining of blood vessels—as a central player in post-transplant complications.
While hyperbilirubinemia (jaundice) is common after alloSCT, it has traditionally been viewed through the lens of primary hepatocyte damage. However, the liver's unique vascular structure suggests that bilirubin levels might also reflect endothelial health. This study aimed to define a clinically relevant threshold for early bilirubinemia (EB) and explore its association with systemic endothelial dysfunction and patient outcomes.
Methodology
The study utilized a retrospective design involving two independent centers. A training cohort of 873 patients from the University of Heidelberg (transplanted 2001–2013) was used to establish a prognostic bilirubin cut-off. This cut-off was then tested in a validation cohort of 388 patients from Charité Berlin (transplanted 2013–2015).
Researchers employed maximally selected log-rank statistics to identify the bilirubin level within the first 28 days (days 0–28) that best predicted NRM. They also analyzed longitudinal serum samples for endothelial and inflammatory biomarkers, including Angiopoietin-2 (ANG2), IL-18, CXCL8, and ST2, and calculated the Endothelial Activation and Stress Index (EASIX) score: (LDH × Creatinine) / Platelets.
Results
The optimal threshold for early bilirubinemia was determined to be 3.6 mg/dL (61.6 µM). Patients exceeding this level within the first 28 days post-transplant exhibited significantly poorer clinical outcomes.
As shown in Figure 1, EB was a potent predictor of both NRM and OS. In multivariable analysis, EB was associated with a Hazard Ratio (HR) of 1.60 for OS (p < 0.001) and a Cause-Specific Hazard Ratio (CSHR) of 2.14 for NRM (p = 0.004). Notably, this predictive power remained significant even after excluding patients with known endothelial complications such as sinusoidal obstruction syndrome (SOS/VOD) or transplant-associated microangiopathy (TAM). Interestingly, EB did not significantly impact the time to relapse (TTR), confirming that its effect on survival is primarily driven by non-relapse complications.
The study also found a strong correlation between EB and biomarkers of endothelial stress. High pre-transplant and day 0 EASIX scores were predictive of developing EB. Furthermore, EB correlated with elevated post-transplant levels of ANG2, IL-18, CXCL8, and ST2, suggesting a systemic inflammatory and vascular "signature."
Discussion
These findings suggest that early bilirubinemia is more than a simple marker of liver injury; it serves as a clinical indicator of systemic endothelial distress. The association with pre-transplant EASIX scores and ANG2 levels implies that some patients possess a "vulnerable" endothelium even before conditioning begins. The subsequent "second hit" of the transplant procedure then triggers a cascade of vascular failure that manifests as EB.
Identifying EB as an endothelial complication has significant clinical implications. It provides a simple, routine laboratory marker (total bilirubin > 3.6 mg/dL) to identify high-risk patients early in the transplant course. Future clinical trials could utilize EB or the EASIX score to select patients for preemptive endothelial-protective interventions, such as defibrotide or targeted anti-inflammatory therapies.
While the retrospective nature of this study limits causal conclusions, the robust validation across two independent cohorts underscores the clinical relevance of the 3.6 mg/dL threshold. Further research is needed to elucidate the exact molecular pathways connecting systemic endothelial dysfunction to bilirubin release.
Conclusion
Early bilirubinemia (EB ≥ 3.6 mg/dL) is a robust, independent predictor of mortality after alloSCT. Its strong correlation with endothelial biomarkers and risk scores supports the hypothesis that EB is a manifestation of systemic endothelial dysfunction. Monitoring bilirubin levels in the first month post-transplant offers a valuable window for risk stratification and potential therapeutic intervention.
Summary updated